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Abstract: Osteoporosis is a chronic condition that generally requires long-term therapy for 
fracture risk reduction to become apparent. Although the bisphosphonates have made a major 
contribution to how clinicians manage osteoporosis, compliance with therapy has generally 
been less in the real-world setting than seen in clinical trials. Less-frequently administered 
dosage regimens or nonoral routes may enhance compliance and so maximize the therapeutic 
beneﬁ  t of bisphosphonates. Ibandronate is a nitrogen-containing bisphosphonate, whose high 
potency allows it to be administered orally or intravenously with extended dosing intervals. 
This paper will review the role of intravenous ibandronate in the treatment of postmenopausal 
osteoporosis.
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Introduction
The bisphosphonates have made a major contribution to how clinicians manage 
osteoporosis and are regarded as ﬁ  rst-line therapy. Their chemical structure comprises 
of two phosphate groups linked through a central carbon atom, with the various 
members of the class distinguished by the two side chains that bind to it. Two classes of 
bisphosphonates are distinguished on the basis of their side chains; those that contain a 
nitrogen atom (eg, alendronate, risedronate, ibandronate, and zoledronate) (Figure 1), and 
those that do not (eg, etidronate and clodronate). Oral bisphosphonates are associated 
with poor adherence in the long term, possibly due to inconvenient dosing (Bauss and 
Russell 2004). Therefore, less-frequent, intermittent dosing may offer beneﬁ  ts for the 
patient and reduce fracture risk.
Ibandronate is a nitrogen-containing bisphosphonate with a strong afﬁ  nity for 
bone that potently inhibits osteoclast mediated bone resorption. Oral ibandronate 
is rapidly absorbed (tmax <1 hour), with low bioavailability (0.63%) that is further 
reduced in the presence of food by up to 90% (Barrett et al 2004). Ibandronate has 
a wide therapeutic index and is not metabolized and therefore has a low potential 
for drug interactions (Barrett et al 2004). Due to its metabolic stability, ibandronate 
is eliminated from the blood by partitioning into bone (40%–50%) and through 
renal clearance (approximately 60 mL/minute). The renal clearance of ibandronate 
is linearly related to creatinine clearance. The sequestration of ibandronate in bone 
(volume of distribution >90 L) results in a multiphasic elimination (t1/2 range of 
approximately 10–60 hours), characterized by the slow release of ibandronate from 
the bone compartment. The potency of ibandronate and its sequestration into bone 
allows it to be administered orally or intravenously, the latter as a bolus injection 
over 15–30 seconds, both with extended dosing intervals (Schimmer and Bauss 
2003). This review will focus on the intravenous (iv) administration of ibandronate 
and review its preclinical and clinical data.Clinical Interventions in Aging 2007:2(1) 66
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Preclinical and nonosteoporotic 
clinical studies
Although some other currently available bisphosphonates can 
be administered by iv injection, slow infusions are generally 
required due to renal safety concerns. Indeed, acute renal 
failure has been observed with some bisphosphonates given 
by rapid iv administration or at high doses (Bounameaux 
et al 1983; Dumon et al 1991; O’Sullivan et al 1994). 
However, unlike other bisphosphonates, ibandronate can 
be administered by an iv bolus injection without adversely 
affecting renal function. Pfister and colleagues (2003), 
have compared the potential for subclinical renal damage 
to accumulate to clinically relevant levels when minimally 
nephrotoxic doses of ibandronate (1 mg/kg) or zoledronate 
(1 mg/kg or 3 mg/kg) were given intermittently to rats, with 
a between-dose interval of 3 weeks or as a single dose by 
iv injection over 25 weeks. A single dose and intermittent 
dosing of ibandronate resulted in a similar incidence (one 
of six and two of six rats, respectively) and severity score 
(1.0 for both) of proximal tubular degeneration and single cell 
necrosis. Importantly, no accumulation of histopathological 
renal damage was observed. In contrast, intermittent dosing 
of zoledronate induced a higher incidence (six of six rats) and 
severity score (3.0) of histological renal damage compared 
with single dosing (four of six rats and 1.3 respectively).
The renal safety of ibandronate has also been demonstrated 
in human studies in the oncology setting with much higher 
doses than those used in osteoporosis (Pecherstorfer and 
Diel 2004). In clinical trials of patients with malignant 
hypercalcemia or metastatic bone disease due to breast 
cancer, 2 hour infusions of ibandronate at doses of up to 
6 mg had a low potential for renal events (Pecherstorfer 
et al 2003), with a renal tolerability proﬁ  le similar to placebo 
(Body et al 2003, 2006; Lyubimova et al 2003). In pilot 
studies, repeated daily infusions of ibandronate (4 mg infused 
over 2 hours for 4 consecutive days or 6 mg infused over 1 
hour for 3 consecutive days) for severe metastatic bone pain 
were not associated with renal toxicity (Pecherstorfer and 
Diel 2004). Studies of healthy volunteers and patients with 
metastatic bone disease related to breast cancer or multiple 
myeloma also conﬁ  rmed the safety of single 15 minute 
infusions of 6 mg ibandronate (Neugebauer et al 2001; Body 
et al 2004). In addition, the risk of renal dysfunction was not 
increased with single and rapid bolus injections of 2 mg or 
3 mg ibandronate in patients with skeletal metastases (Body 
et al 2003; Pecherstorfer and Diel 2004).
Intravenous ibandronate has been shown to protect 
against ovariectomy-related bone loss in animal studies. In 
rats, iv ibandronate inhibited bone resorption and increased 
bone mass in the tibial metaphysis without affecting 
mineralization (Muhlbauer et al 1991). A study of 66 female 
cynomolgus monkeys, aged 9 years and older, was performed 
in which the monkeys were ovariectomized or sham operated. 
Intravenous bolus injections of ibandronate at doses of 
10 μg/kg, 30 μg/kg, or 150 μg/kg or placebo were administered 
at 30 day intervals (corresponding to intervals of 3 months 
in humans), starting from the time of ovariectomy and 
followed for 16 months (Smith et al 2003). Ovariectomy 
significantly decreased bone mass at the lumbar spine, 
proximal femur, femoral neck and radius, and increased bone 
turnover in a time-dependent manner. Ibandronate bolus 
injections administered at 30 μg/kg every 30 days prevented 
ovariectomy-induced osteopenia. Ovariectomy-induced 
increases in bone turnover (as determined by activation 
frequency, bone formation rate, and biochemical markers 
of bone turnover) were suppressed on treatment and bone 
Figure 1 Generic chemical structure of a bisphosphonate and of ibandronate, rise-
dronate, alendronate and zoledronate. In all cases R1 resembles a hydroxyl group 
while R2 is either an alkylamine (ibandronate and alendronate) or an acrylamine 
(risedronate and zoledronate). Copyright © 2004. Reproduced with permission 
from Springer Science and Business Media. Bauss F, Russell RG. 2004. Ibandronate in 
osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int, 
15:423–33.Clinical Interventions in Aging 2007:2(1) 67
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mass, architecture (assessed by histomorphometry) and bone 
strength were preserved at clinically relevant sites (Smith 
et al 2003). Strength was assessed by compression testing 
to failure of the ﬁ  rst lumbar vertebra and the femur load to 
failure. Treatment with high-dose, iv bolus injections of 
ibandronate (150 μg/kg/dose) further increased bone mass 
and improved bone strength at both the spine and femoral 
neck, without adversely affecting bone quality. In contrast, 
treatment with a 10 μg/kg/dose only partially prevented the 
ovariectomy induced effects.
Clinical trials with iv ibandronate 
in osteoporosis
With regard to iv ibandronate, Thiébaud and colleagues (1997) 
ﬁ  rst investigated its efﬁ  cacy in postmenopausal osteoporosis 
in a dose-ranging, randomized, placebo-controlled study of 
125 women (mean age, 64 years). The groups comprised 
placebo or ibandronate at doses of 0.25 mg, 0.5 mg, 1 mg, or 
2 mg administered every 3 months and all patients received 
calcium supplementation. Lumbar spine bone mineral 
density (BMD) showed a small nonsigniﬁ  cant increase in 
the placebo group by 12 months (+0.85%). For ibandronate 
the increases in lumbar spine BMD were 2.4%, 3.5%, 3.7%, 
and 5.2% after 12 months in a dose-dependent order. There 
was no signiﬁ  cant difference between ibandronate groups, 
but the increases were statistically signiﬁ  cantly different from 
placebo for the 0.5 mg (p < 0.006), 1 mg (p < 0.004), and 2 mg 
(p < 0.001) groups and there was a clear trend favoring the 2 
mg dose at 12 months (Figure 2). There were no signiﬁ  cant 
changes with ibandronate in femoral neck BMD compared 
with placebo, but total hip and trochanter BMD showed dose-
dependent signiﬁ  cant changes. The increases were 1.8% and 
2.9% for total hip and 2.7% and 4.2% for the trochanter in 
the 1 mg and 2 mg groups, respectively. Urinary excretion 
of C-telopeptide and N-telopeptide decreased after 1 month 
in all ibandronate groups in a dose-dependent fashion (mean 
change: –16% placebo, –33% 0.25 mg, –41% 0.5 mg, –57% 
1 mg, and –66% 2 mg), but there was a gradual increase 
towards baseline thereafter. However, for the 2 mg dose, by 3 
months (just prior to the next injection), there was a persistent 
and signiﬁ  cant reduction in these markers of bone resorption 
compared with placebo of about 40% (p < 0.003) (Figure 3). 
It should be noted that the study did not extend beyond 
12 months and the power of the study to show differences 
between groups was modest with only approximately 25 
subjects in each group. Nevertheless, based upon these data, 
approval was given for a phase III fracture trial using the 
0.5 mg and 1 mg doses over 3 years, but not the 2 mg dose.   
Importantly, subsequent studies discussed below conﬁ  rm 
a superior BMD and marker response for the 2 mg dose, 
especially beyond 12 months.
The subsequent phase III fracture trial was a double-blind, 
placebo-controlled, randomized study in 2862 women (aged 
55–76 years) with postmenopausal osteoporosis deﬁ  ned by 
one to four prevalent vertebral fractures and a lumbar spine 
T-score between –2.0 and –5 in at least one vertebral body 
(Recker et al 2004). The latter criterion is different to most 
other studies in postmenopausal osteoporosis which have 
usually required a T-score below –2 or –2.5 in the integrated 
lumbar spine BMD (ie, L1–L4 or L2–L4). All participants 
received daily vitamin D (400 IU) and calcium (500 mg) 
supplementation. At the two doses studied (0.5 mg and 
1 mg quarterly), iv ibandronate produced dose-dependent, but 
comparatively small, increases in lumbar spine BMD (2.9% 
and 4.0%, respectively) over 3 years compared with placebo. 
At the total hip the increases were also modest at 2.3% 
and 3.6% compared with placebo, respectively. Similarly, 
decreases in biochemical markers of bone resorption, 
measured just before the next dose, were modest at 41.4% 
and 45.0% from baseline respectively and were 7.2% and 
10.8% relative to placebo for serum concentration of the 
Figure 2 Changes (% ± SEM) in lumbar spine BMD (L2–L4) before and 3, 6, 9, and 
12 months after iv injection of ibandronate or placebo. The arrows indicate the 
time of iv injection of study drug. Copyright © 1997. Reproduced with permission 
from Elsevier. Thiébaud D, Burckhardt P, Kriegbaum H, et al. 1997. Three monthly 
intravenous injections of ibandronate in the treatment of postmenopausal osteopo-
rosis. Am J Med, 103:298–307.
Abbreviations: BMD, bone mineral density; iv, intravenous; SEM, standard error 
of mean. Clinical Interventions in Aging 2007:2(1) 68
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C-terminal collagen I telopeptide (sCTX) and importantly, as 
in the Thiébaud study (Thiébaud et al 1997), showed gradual 
recovery towards placebo values by 3 months (Figure 4).
The primary study endpoint was the incidence of new 
morphometric vertebral fractures at 3 years. Although a 
trend towards a reduction in the incidence of new vertebral 
fractures was observed in the active treatment arms compared 
with placebo (10.7%, 8.7%, and 9.2% in the placebo, 0.5 mg, 
and 1 mg groups, respectively), the magnitude of fracture 
reduction was insufﬁ  cient to achieve statistical signiﬁ  cance 
(Recker et al 2004). In the per-protocol (PP) analysis, the 
fracture risk reduction approached statistical signiﬁ  cance 
for the 1 mg dose (26% reduction, p = 0.0549). A similar, 
nonsigniﬁ  cant trend was seen in the incidence of nonvertebral 
and hip fractures but the study was not powered to address 
these endpoints.
It was concluded that optimal fracture efﬁ  cacy most 
likely required more substantial increases in BMD, as well 
as more pronounced suppression of bone turnover and that 
this required higher iv doses of ibandronate. The results of 
a subsequent phase II/III study, IRIS (Intermittent Regimen 
Intravenous Ibandronate Study), discussed below support 
this hypothesis.
A number of other studies of iv ibandronate were 
performed around this time. Stakkestad and colleagues 
(2003) studied the dose response and efficacy of iv 
ibandronate in a different population to previous studies, 
namely early postmenopausal women without osteoporosis, 
ie, this was a prevention study. Six-hundred and twenty-
nine women (mean age 54.75 years) within 10 years of 
their menopause (mean duration 4.3 years) were enrolled 
into this multicenter, double-blind, placebo-controlled trial. 
Patients were stratiﬁ  ed according to time since menopause 
(less than or more than 3 years) and baseline lumbar spine 
BMD (normal or osteopenic) and were randomly allocated 
to receive iv ibandronate 0.5 mg, 1 mg or 2 mg, or placebo 
every 3 months as well as daily calcium supplementation. 
The study was intended to run for 2 years but stopped 
after 1 year when the results of the phase 3 fracture study 
(Recker et al 2004) showed suboptimal efﬁ  cacy with the 
0.5 mg and 1 mg doses. The 12-month data showed a 
Figure 3 Changes (% ± SEM) in C-telopeptide in 2-hour fasting morning urine 
(upper panel) and serum osteocalcin (lower panel) before and 1, 2, 3, 6, 9, 10, 11, 12, 
and 15 months after iv injection of ibandronate or placebo. The arrows indicate the 
time of iv injection of study drug Copyright © 1997. Reproduced with permission 
from Elsevier. Thiébaud D, Burckhardt P, Kriegbaum H, et al. 1997. Three monthly 
intravenous injections of ibandronate in the treatment of postmenopausal osteopo-
rosis. Am J Med, 103:298–307.
Abbreviations: iv, intravenous; SEM, standard error of mean. 
Figure 4 Median change versus placebo (%) in CTX/creatinine excretion with 
1 mg, 0.5 mg ibandronate and placebo iv injections given once every 3 months. 
Copyright © 2004. Reproduced with permission from Elsevier. Recker RR, Stakkes-
tad J, Chesnut C, et al. 2004. Insufﬁ  ciently dosed intravenous ibandronate injections 
are associated with suboptimal antifracture efﬁ  cacy in postmenopausal osteoporo-
sis. Bone, 34:890–9.
Abbreviations: CTX, C-terminal collagen I telopeptide; iv, intravenous.Clinical Interventions in Aging 2007:2(1) 69
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dose-dependent gain in lumbar spine BMD from baseline 
of 2.5%, 1.8%, and 1.0% in the groups receiving 2 mg, 1 mg, 
and 0.5 mg ibandronate, respectively, compared with a 
loss of BMD of 0.4% in the women in the placebo group 
(p = 0.0001 for each ibandronate dose vs placebo). The 
largest BMD gains occurred in women with osteopenia 
receiving 2 mg ibandronate. Similarly, at the hip, all three 
doses of ibandronate produced signiﬁ  cantly better gains in 
BMD than placebo (p < 0.05), with the greatest gains in the 
women with osteopenia receiving the 2 mg dose. Intravenous 
ibandronate concomitantly and dose-dependently suppressed 
markers of bone turnover in comparison with placebo. sCTX 
and urinary CTX/creatinine were reduced by 42% and 50% 
after 12 months for patients receiving 2 mg ibandronate every 
3 months compared with 9% and 7% for patients receiving 
placebo plus calcium, respectively. Myalgia was reported 
in 22% of patients receiving the 2 mg ibandronate dose 
compared with 4% in the placebo group.
Ringe and colleagues (2003) investigated the use of 
iv ibandronate in patients with glucocorticoid-induced 
osteoporosis in an open-label study. A total of 115 
participants, all receiving at least 7.5 mg prednisone daily, 
were assigned to receive daily calcium supplements (500 mg) 
plus either quarterly ibandronate (2 mg) injections or daily 
oral alfacalcidol (1 μg) for 3 years. Intravenous ibandronate 
produced signiﬁ  cantly greater increases in mean BMD at the 
lumbar spine (13.3% vs 2.6%, respectively; p < 0.001), and 
femoral neck (5.2% vs 1.9%, respectively; p < 0.001) than 
daily oral alfacalcidol, at 3 years, relative to baseline. It is 
worth noting that these increases in BMD are substantially 
greater than might be expected based upon previous studies 
in postmenopausal osteoporosis, but no explanation was 
provided. Biochemical markers of bone turnover were not 
measured. Despite the study not being powered for fracture, 
at 3 years the incidence of patients with new vertebral 
fractures was signiﬁ  cantly lower in the patients receiving 
ibandronate relative to those taking alfacalcidol (8.6% vs 
22.8%, respectively; p = 0.043). Patients treated with iv 
ibandronate also experienced less back pain (p < 0.001) and 
height loss (p = 0.001) than those receiving oral alfacalcidol. 
Despite the use of corticosteroids in all subjects, which 
might be expected to modify expression of side effects, a 
higher incidence of myalgia/arthralgia was observed in the 
ibandronate group (7.0% and 13.8%, respectively), although 
this adverse event was generally mild, temporary, and 
manageable, and was mostly seen in the ﬁ  rst 6 months of 
treatment. It was concluded that intermittent iv ibandronate 
injections are efﬁ  cacious and well tolerated in glucocorticoid-
treated patients.
The above two studies had BMD as their primary 
endpoint but other studies have addressed the effects of 
iv ibandronate primarily on bone turnover. For example, 
Christiansen and colleagues (2003) studied bone turnover in 
73 healthy postmenopausal women following iv ibandronate. 
The study had three groups, either no treatment or an iv 
injection of 1 mg or 2 mg ibandronate on days 0 and 84, 
with follow-up to 168 days. Bone turnover was assessed 
by sCTX and osteocalcin at 19 consecutive timepoints. 
Mean sCTX decreased rapidly reaching a nadir 7 days after 
ibandronate. Maximal changes from baseline in the 1 mg and 
2 mg ibandronate groups were –81% and –90%, respectively 
(p < 0.001). Two weeks after drug administration, sCTX 
started to rise in both treatment groups, reaching –16% and 
–20% below baseline by day 84, ie, immediately before the 
second administration. In contrast, osteocalcin showed a 
slower but progressive decrease over time reaching a nadir 
at –35% inhibition after 5 months. The authors interpreted 
this study as indicating that the relatively short inhibition 
of bone resorption in comparison with bone formation may 
explain its lack of efﬁ  cacy in the phase III trial (Recker et al 
2004), although the physiological relevance of the relative 
changes in formation versus resorption markers remains 
unclear. Moreover, it is worth noting that although the study 
was randomized, it was not double-blind, had relatively low 
power (sample size 23 or 25 in each group) and only relatively 
short follow-up (6 months).
Returning to BMD endpoints, the IRIS study examined the 
dose-response relationship with intermittent iv ibandronate 
injections in 520 postmenopausal osteoporotic women 
(aged 55–75 years, >5 years since menopause) (Adami 
et al 2004). Participants were randomized to receive either 
quarterly 2 mg (n = 261) or 1 mg (n = 131) ibandronate or 
placebo (n = 128) iv injections. After 1 year, ibandronate 
therapy produced signiﬁ  cant and dose-dependent increases 
in lumbar spine and hip BMD and decreases in biochemical 
markers of bone turnover. Lumbar spine BMD increased by 
2.8% and 5.0% in the 1 mg and 2 mg groups, respectively 
and decreased by 0.04% in the placebo group (Figure 5). 
Similarly, total hip BMD increased by 2.2%, 2.9%, and 
0.6%, in the corresponding groups, respectively. These BMD 
data are remarkably similar to that reported in the Thiébaud 
study (Thiébaud et al 1997). Serum and urinary CTX, 
reﬂ  ecting bone resorption, decreased by 62.5% and 61%, 
respectively, with the 2 mg dose, and by 43.5% and 42%, Clinical Interventions in Aging 2007:2(1) 70
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respectively, with the 1 mg dose (Figure 6). It was noted that 
the IRIS study reported a greater magnitude of suppression 
of biomarkers than in the Thiébaud (1997) or Christiansen 
(2003) studies. An explanation for these differences included 
the reporting of mean values in the latter two studies as 
opposed to median values and the lack of use of calcium 
supplementation in the Christiansen study (2003). It was 
concluded that the IRIS study ﬁ  ndings demonstrate that the 
2 mg dose provided signiﬁ  cantly greater efﬁ  cacy, using these 
surrogates, than the 1 mg dose. Intravenous ibandronate was 
well tolerated with a similar incidence of adverse events to 
placebo and no indication of renal toxicity. In summary, a 
clear dose-response relationship was again observed and this 
study showed that the 2 mg ibandronate regimen provided 
signiﬁ  cantly greater BMD increases and signiﬁ  cantly greater 
suppression of bone resorption markers than the 1 mg dose 
used in the previous phase 3 fracture prevention study.
As noted above, ibandronate has been studied in phase 
III trials with daily and intermittent oral and iv formulations. 
Although this review deals primarily with iv ibandronate, 
it is important to note that in a study of 2946 women with 
postmenopausal osteoporosis, oral ibandronate, either 
continuously (2.5 mg/day) or intermittently (20 mg given 
every other day for the ﬁ  rst 24 days, followed by 9 weeks 
without active drug) produced changes in BMD comparable 
with those found with oral alendronate or risedronate. In the 
primary endpoint of this study, oral ibandronate reduced 
vertebral fracture risk at 3 years by 62% with daily therapy 
and 50% with intermittent therapy (Chesnut et al 2004). 
A subsequent randomized, double-blind, double-dummy, 
phase III, noninferiority study (DIVA) was performed with 
two regimens of intermittent iv injections of ibandronate 
(2 mg every 2 months and 3 mg every 3 months) compared 
with 2.5 mg daily oral ibandronate. The latter was chosen 
as a comparator because of its proven antifracture efﬁ  cacy 
(Chesnut et al 2004). The cumulative dose over 12 months 
with both ibandronate regimens was the same, ie, 12 mg, 
but study of a lower dose with shorter dosing interval 
(2 mg every 2 months) as well as the 3-monthly dose was 
to address the issue of recovery of bone turnover markers 
observed in the previous Thiébaud (1997) and Recker (2004) 
Figure 5 Mean (SD) change (%) from baseline in lumbar spine (L1–L4) BMD; 
ITT analysis. Copyright © 2004. Reprinted with permission from Elsevier. Adami S, 
Felsenberg D, Christiansen C, et al. 2004. Efﬁ  cacy and safety of ibandronate given by 
intravenous injection once every 3 months. Bone, 34:881–9.
Abbreviations: BMD, bone mineral density; ITT, intention-to-treat; SD, standard 
deviation. 
Figure 6 Median change (%) from baseline in serum CTX (A), urinary CTX/creati-
nine (B), and serum osteocalcin (C); ITT analysis. Copyright © 2004. Reprinted with 
permission from Elsevier. Adami S, Felsenberg D, Christiansen C, et al. 2004. Efﬁ  cacy 
and safety of ibandronate given by intravenous injection once every 3 months. Bone, 
34:881–9.
Abbreviations: CTX, C-terminal collagen I telopeptide; ITT, intention-to-treat; 
iv, intravenous.Clinical Interventions in Aging 2007:2(1) 71
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studies. The DIVA study group comprised 1395 women 
(aged 55–80 years) who were at least 5 years postmenopausal, 
with osteoporosis (deﬁ  ned as a lumbar spine BMD T-score 
<–2.5). Participants also received daily calcium (500 mg) 
and vitamin D (400 IU). The primary endpoint was change 
from baseline in lumbar spine BMD at 12 months. Changes 
in hip BMD and in the level of sCTX were also measured, 
as were safety and tolerability. At 12 months, mean lumbar 
spine BMD increased by 5.1% in 353 patients receiving 2 mg 
ibandronate every 2 months, 4.8% in 365 patients receiving 
3 mg ibandronate every 3 months and 3.8% in 377 patients 
receiving 2.5 mg daily oral ibandronate (Figure 7) (Delmas 
et al 2006). This was a noninferiority study following the 
same design as the bridging studies for weekly alendronate 
and risedronate (Schnitzer et al 2000; Brown et al 2002). Both 
of the ibandronate regimens were not only noninferior, but 
also superior (p < 0.001) to the daily oral regimen (Figure 8) 
(Delmas et al 2006). Hip BMD increased at all sites and was 
greater in the groups receiving iv ibandronate than in the 
group receiving daily oral ibandronate. Large decreases in 
the sCTX level were observed in all arms of the study and 
Figure 7 Mean change from baseline in lumbar spine and proximal femur BMD 
after 1 year in the PP population. Bars show the 95% CI (Delmas et al 2006).
Abbreviations: BMD, bone mineral density; CI, conﬁ  dence interval; 
PP, per-protocol; q2mo, every 2 months; q3mo, every 3 months.
Figure 8 Noninferiority analysis of mean change (%) from baseline in lumbar spine 
(L2–L4) BMD after 1 year in the PP population. Squares and horizontal lines show 
the mean difference (and 95% CI) between each group receiving iv medication and 
the group receiving oral medication (expressed as iv minus oral) (Delmas et al 
2006).
Abbreviations: BMD, bone mineral density; CI, conﬁ  dence interval; iv, intravenous; 
PP, per-protocol; q2mo, every 2 months; q3mo, every 3 months. 
Table 1 Change (%) from baseline in sCTX levels in the PP population (Delmas et al 2006)
  Ibandronate iv    Ibandronate iv    Ibandronate oral
  2 mg every 2 months    3 mg every 3 months    2.5 mg daily
Month  Median (95% CI)  N  Median (95% CI)  N  Median (95% CI)  N
2  –47.1 (–51.0, –43.8)  348  –    –45.0 (–48.7, –40.5)  181
3  –    –43.2 (–45.9, –40.8)  356  –54.1 (–57.8, –48.7)  192
4  –61.4 (–63.4, –58.4)  349  –    –57.6 (–66.7, –50.0)  180
6  –65.1 (67.4, –62.5)  346  –58.4 (–61.5, –55.2)  353  –62.5 (–65.3, –60.0)  372
12  –64.6 (–67.2, –62.5)  345  –58.6 (–61.5, –55.4)  352  –62.6 (–66.0, –58.9)  368
Abbreviation: CI, conﬁ  dence interval; iv, intravenous; PP, per-protocol; sCTX, serum C-terminal collagen I telopeptide.
were similar in all three groups at 6 and 12 months (Table 1). 
Neither of the iv regimens affected renal function, but there 
was a higher incidence of ﬂ  u-like illness in the iv ibandronate 
groups (5.1% and 4.9% in the 2-monthly and 3-monthly 
groups) versus 1.1% in the daily oral group but this mostly 
occurred at the time of the ﬁ  rst injection.
The 2 year results of the DIVA study conﬁ  rm that as 
assessed by BMD and markers, iv ibandronate is at least 
as effective as the oral regimen of 2.5 mg daily, which has 
proven antifracture efﬁ  cacy (Eisman et al 2006). Since 
3-monthly dosing is likely to be more convenient than 
2-monthly dosing, 3 mg quarterly is the dosing regimen 
approved for use in the US and Europe.
Conclusion
Intravenous ibandronate at a quarterly dose of 3 mg is 
effective in normalizing bone turnover and increasing BMD 
at clinically relevant sites in women with postmenopausal Clinical Interventions in Aging 2007:2(1) 72
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osteoporosis with effects on these surrogate markers that 
are equivalent to or superior to those seen with daily oral 
therapy which has proven antifracture efﬁ  cacy. Although 
iv administration is associated with a higher incidence of 
ﬂ  u-like illness, this is usually mild and settles after the ﬁ  rst 
injection. Administration of iv ibandronate may avoid the 
problems of poor adherence in those subjects intolerant 
of oral bisphosphonates and provides a further option for 
treatment of osteoporosis.
References
Adami S, Felsenberg D, Christiansen C, et al. 2004. Efﬁ  cacy and safety 
of ibandronate given by intravenous injection once every 3 months. 
Bone, 34:881–9.
Barrett J, Worth E, Bauss F, et al. 2004. Ibandronate: a clinical pharmacological 
and pharmacokinetic update. J Clin Pharmacol, 44:951–65.
Bauss F, Russell RG. 2004. Ibandronate in osteoporosis: preclinical data and 
rationale for intermittent dosing. Osteoporos Int, 15:423–33.
Body JJ, Diel IJ, Lichinitser MR, et al. 2003. Intravenous ibandronate 
reduces the incidence of skeletal complications in patients with breast 
cancer and bone metastases. Ann Oncol, 14:1399–405.
Body JJ, Diel IJ, Tripathy D, et al. 2006. Intravenous ibandronate does 
not affect time to renal function deterioration in patients with skeletal 
metastases from breast cancer: phase III trial results. Eur J Cancer 
Care, 15:299–302.
Body JJ, Lichinitser M, Andreeva N, et al. 2004. Safety of an intravenous 
(i.v.) dose of ibandronate followed by daily oral dosing in metastatic 
bone disease: Results of an open-label study. J Clin Oncol, 22:60S.
Bounameaux HM, Schifferli J, Montani JP, et al. 1983. Renal failure 
associated with intravenous diphosphonates. Lancet, 1:471.
Brown JP, Kendler DL, McClung MR, et al. 2002. The efficacy 
and tolerability of risedronate once a week for the treatment of 
postmenopausal osteoporosis. Calcif Tissue Int, 71:103–11.
Chesnut CH, Skag A, Christiansen C, et al. 2004. Effects of oral ibandronate 
administered daily or intermittently on fracture risk in postmenopausal 
osteoporosis. J Bone Miner Res, 19:1241–9.
Christiansen C, Tanko LB, Warming L, et al. 2003. Dose dependent effects 
on bone resorption and formation of intermittently administered 
intravenous ibandronate. Osteoporos Int, 14:609–13.
Delmas PD, Adami S, Strugala C, et al. 2006. Intravenous ibandronate 
injections in postmenopausal osteoporosis: 1-year ﬁ  ndings from the 
DIVA study. Arthritis Rheum, 54:1838–46.
Dumon JC, Magritte A, Body JJ. 1991. Efficacy and safety of the 
bisphosphonate tiludronate for the treatment of tumor-associated 
hypercalcemia. Bone Miner, 15:257–66.
Eisman J, Garcia-Hernandez P, Ortiz-Luna G, et al. 2006. Intermittent 
intravenous ibandronate injections are an effective treatment option in 
postmenopausal osteoporosis: 2-year results from DIVA. Osteoporos 
Int, 17(Suppl. 2):S212; [abstract P316SA].
Lyubimova NV, Kushlinsky NE, Lichinitser M 2003. Long-term treatment 
with intravenous ibandronate does not effect renal function in breast 
cancer patients with metastatic bone disease. Support Care Cancer, 
11:416; [abstract A–107].
Mühlbauer RC, Bauss F, Schenk R, et al. 1991. BM 21.0955, a potent 
new bisphosphonate to inhibit bone resorption. J Bone Miner Res, 
6:1003–11.
Neugebauer G, Koehler W, Akinkunmi L, et al. 2001. Inﬂ  uence of peak 
ibandronic acid concentrations after 6 mg i.v. administration with 
shortened infusion time (15 and 30 minutes) on renal safety in man. 
Proc Am Soc Clin Oncol, 20:122A; [abstract 486].
O’Sullivan TL, Akbari A, Cadnapaphornchai P. 1994. Acute renal failure 
associated with the administration of parenteral etidronate. Ren Fail, 
16:767–73.
Pecherstorfer M, Diel IJ. 2004. Rapid administration of ibandronate does 
not affect renal functioning: evidence from clinical studies in metastatic 
bone disease and hypercalcaemia of malignancy. Support Care Cancer, 
12:877–81.
Pecherstorfer M, Steinhauer EU, Rizzoli R, et al. 2003. Efﬁ  cacy and safety 
of ibandronate in the treatment of hypercalcemia of malignancy: a 
randomized multicentric comparison to pamidronate. Suppor Care 
Cancer, 11:539–47.
Pﬁ  ster T, Atzpodien E, Bauss F. 2003. The renal effects of minimally 
nephrotoxic doses of ibandronate and zoledronate following single 
and intermittent intravenous administration in rats. Toxicology, 
191:159–67.
Recker RR, Stakkestad J, Chesnut C, et al. 2004. Insufﬁ  ciently dosed 
intravenous ibandronate injections are associated with suboptimal 
antifracture efﬁ  cacy in postmenopausal osteoporosis. Bone, 34:890–9.
Ringe JD, Dorst A, Faber H, et al. 2003. Intermittent intravenous ibandronate 
injections reduce vertebral fracture risk in corticosteroid-induced 
osteoporosis: results from a long-term comparative study. Osteoporos 
Int, 14:801–7.
Schimmer RC, Bauss F 2003. Effect of daily and intermittent use of 
ibandronate on bone mass and bone turnover in postmenopausal 
osteoporosis: a review of three phase II studies. Clin Ther, 25:19–34.
Schnitzer T, Bone HG, Crepaldi G, et al. 2000. Therapeutic equivalence 
of alendronate 70 mg once-weekly and alendronate 10 mg daily in the 
treatment of osteoporosis. Alendronate Once-Weekly Study Group. 
Aging (Milano), 12:1–12.
Smith SY, Recker RR, Hannan M, et al. 2003. Intermittent intravenous 
administration of the bisphosphonate ibandronate prevents bone loss 
and maintains bone strength and quality in ovariectomized cynomolgus 
monkeys. Bone, 32:45–55.
Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. 2003. Intravenous 
ibandronate injections given every three months: a new treatment 
option to prevent bone loss in postmenopausal women. Ann Rheum 
Dis, 62:969–75.
Thiébaud D, Burckhardt P, Kriegbaum H, et al. 1997. Three monthly 
intravenous injections of ibandronate in the treatment of postmenopausal 
osteoporosis. Am J Med, 103:298–307.